Studies in rodent models of cancer and infectious diseases have demonstrated that the adoptive transfer of T cells of defined antigen specificity and function can establish or augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection. However, in most clinical studies the infusion of large numbers of cultured T cells or T cell clones has failed to completely eradicate tumors or provide long-term control of infection. This is in part due to the inability with current approaches to establish an immune response of sufficient magnitude and persistence by adoptive transfer for sustained therapeutic efficacy. Studies of cytokines such as IL15 that regulate lymphocyte growth and survival, and of homeostatic mechanisms that operate to maintain lymphocyte numbers but permit expansion of antigen-specific T cells in response to in vivo stimulation have provided insights into strategies that might be employed to better establish T cell immunity by the adoptive transfer of T cell clones. The goals of this proposal are to develop strategies that improve the establishment of a persistent high-level antigen-specific T cell response in vivo by the adoptive transfer of CD8+ T cell clones, and can be applied to clinical trials of T cell therapy for cancer. The studies will be performed in non-human primates (Macacca nemestrina), and utilize CD8+ T cell clones specific for rhesus cytomegalovirus (rhCMV) as a model target antigen. Culture techniques that are routinely used to propagate human T cells for clinical adoptive T cell therapy will be employed to improve our ability to directly translate the results to studies of T cell therapy for human malignancy and infection.
The specific aims are: 1). To determine the effect of the in vivo administration of interleukin (IL2) and interleukin 15 (IL15) on the persistence, function, and migration of adoptively transferred CD8+ antigen-specific T cell clones. 2). To determine the effects of lymphodepletion prior to T cell transfer on the persistence, function, and migration of adoptively transferred CD8+ antigen-specific T cell clones. 3). To determine whether the magnitude and persistence of a CD8+ cytotoxic T cell response established by adoptive transfer can be enhanced by antigen stimulation in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA114536-04
Application #
7359627
Study Section
Special Emphasis Panel (ZRG1-CII (01))
Program Officer
Mccarthy, Susan A
Project Start
2005-04-01
Project End
2010-02-28
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
4
Fiscal Year
2008
Total Cost
$386,144
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Salter, Alexander I; Ivey, Richard G; Kennedy, Jacob J et al. (2018) Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal 11:
Srivastava, Shivani; Riddell, Stanley R (2018) Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. J Immunol 200:459-468
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Sommermeyer, D; Hill, T; Shamah, S M et al. (2017) Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 31:2191-2199
Pollack, Seth M; He, Qianchuan; Yearley, Jennifer H et al. (2017) T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 123:3291-3304
Sadelain, Michel; Rivière, Isabelle; Riddell, Stanley (2017) Therapeutic T cell engineering. Nature 545:423-431
Balakrishnan, Ashwini; Goodpaster, Tracy; Randolph-Habecker, Julie et al. (2017) Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res 23:3061-3071
Sommermeyer, D; Hudecek, M; Kosasih, P L et al. (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30:492-500
Liu, Lingfeng; Sommermeyer, Daniel; Cabanov, Alexandra et al. (2016) Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol 34:430-4
Paszkiewicz, Paulina J; Fräßle, Simon P; Srivastava, Shivani et al. (2016) Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest 126:4262-4272

Showing the most recent 10 out of 43 publications